The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Galectin Therapeutics Inc shares valued at $172,223 were purchased by HAROLD SHLEVIN on Dec 17 ’25. At $6.97 per share, HAROLD SHLEVIN acquired 24,706 shares.
Also, Jamil Khurram purchased 21,479 shares, netting a total of over 151,212 in proceeds.
Before that, LEWIS JOEL had added 40,000 shares to its account. In a trade valued at $282,244, the Officer bought Galectin Therapeutics Inc shares for $7.06 each.
Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid August. As of February 13, 2019, B. Riley FBR has initiated its “Buy” rating for GALT. Earlier on December 07, 2017, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for GALT stock.
Analyzing GALT Stock Performance
On last trading session, Galectin Therapeutics Inc [NASDAQ: GALT] rose 4.35% to $6.47. The stock’s lowest price that day was $6.46, but it reached a high of $7.13 in the same session. During the last five days, there has been a surge of approximately 17.85%. Over the course of the year, Galectin Therapeutics Inc shares have jumped approximately 206.64%. Shares of the company reached a 52-week high of $7.13 on 12/17/25 and a 52-week low of $1.07 on 01/14/25.
Support And Resistance Levels for Galectin Therapeutics Inc (GALT)
According to the 24-hour chart, there is a support level at 6.24, which, if violated, would cause prices to drop to 6.01. In the upper region, resistance lies at 6.91. The next price resistance is at 7.36. RSI (Relative Strength Index) is 59.32 on the 14-day chart, showing neutral technical sentiment.
Is Galectin Therapeutics Inc subject to short interest?
Stocks of Galectin Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 86983.0 shares to 6.82 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 6.9 million shares. A decline of -1.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 16.46 of the overall float, the days-to-cover ratio (short ratio) decline to 16.46.
Which companies own the most shares of Galectin Therapeutics Inc (GALT)?
In terms of Galectin Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 11 in the next 12 months, up nearly 77.42% from the previous closing price of $6.2. Analysts anticipate Galectin Therapeutics Inc stock to reach 11 by 2025, with the lowest price target being 11. On November 28, 2017, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $6.
